Abstract: Foamable dental fluoride compositions containing a water-soluble fluoride component in an amount sufficient to provide from about 0.5 to about 10% by weight available fluoride are disclosed. The compositions include an oil in water emulsion which is preferably dispensed in combination with an aerosol propellant to provide microcell-stable foam which exhibits enhanced foam retention properties. Methods of treating teeth with fluoride and methods of preparing the foam are also disclosed.

Abstract: An adhesive for tissue capable of uniformly forming a high concentration of fibrin so as to provide a high closing effect is disclosed. The adhesive for tissue comprises a fibrinogen solution and a thrombin solution which solutions are separated from each other. The adhesive is to be mixed and spray coated together with a sterile gas and has a volume ratio of the fibrinogen solution to the thrombin solution of about 2:1 to 10:1. This adhesive is to be sprayed together with a sterile gas for the adhesion or closing of living tissue of a human being or animal.

Abstract: The present invention relates to use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and the preparation for this purpose. It is known to use dichlorobenzyl alcohol (2,4-DCBA) as an agent against bacteria and fungi, i.e. as a disinfectant. By the present invention it has, however, surprisingly turned out that dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, is also useful for treatment of inflammation. The invention also relates to a preparation containing dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, for topical treatment of inflammation, which can be applied onto skin or mucosa in the form of an ointment, a cream, a gel or a solution. Thus, the preparation has turned out to be effective against a variety of inflammatory conditions including skin diseases, such as pruritus and psoriasis, insect bites and stings.

Abstract: The present invention relates to oral care compositions, including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, and lozenges (including breath mints), comprising at least a minimally effective amount of chlorite ion, wherein preferably the pH of the final composition is greater than 7 and level of chlorine dioxide or chlorous acid is less than about 50 ppm, preferably is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing gingivitis, plaque, periodontal disease, and/or breath malodor, and/or for the whitening of teeth, in humans or other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity.

Abstract: Topically applicable sunscreen/cosmetic compositions well suited for the synergistically enhanced photoprotection of human skin and/or hair against the damaging effects of UV-irradiation, particularly solar ratiation, comprise synergistically UV-photoprotecting effective amounts of each of (a) at least one benzotriazole compound, (b) at least one bisresorcinyltriazine compound and (c) at least one compound containing at least two benzoazolyl groups per molecule and/or at least one compound containing, per molecule, at least one benzodiazolyl group, formulated into a topically applicable, cosmetically acceptable vehicle, diluent or carrier therefor.

Abstract: In a system for coating human skin, a chemical composition, such as a cosmetic or medical formulation, is uniformly coated over the entire body or selected parts of the body of the person being coated. The system includes atomization of the coating composition, containment of the atomized spray, and residual recovery which together yield a novel method for applying chemical compositions. An improved self-tanning composition is useful in conjunction with the system is also disclosed.

Abstract: The present invention provides the process for accelerating the drying time of a cosmetic makeup, sun protection or nail care compositions which includes introducing at least one volatile organic polyhalogenic solvent into the composition.

Abstract: An antiperspirant product for the human skin, comprising an antiperspirant active for topical application, and an effective amount of a compound which inhibits the acidification mechanism in the eccrine gland to elevate the pH of sweat.

Abstract: A cosmetic composition, preferably an antiperspirant stick, has a carrier liquid which is almost exclusively silicone oil, structured with lanosterol. Instability is avoided by nearly complete exclusion or complete exclusion of silicon-free organic liquids.

Abstract: The invention relates to a process for improving the color fastness of a dyed keratin fiber comprising applying to said fiber (a) at least one dye composition containing, in a medium suitable for dyeing, at least one oxidation base selected from bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols, heterocyclic bases and para-phenylenediamines of formula (I), and the addition salts of these compounds with an acid: in which: R1 represents a hydrogen atom or a C1-C4 alkyl, C1-C4 monohydroxyalkyl, C2-C4 polyhydroxyalkyl, phenyl or 4′-aminophenyl radical, R2 represents a hydrogen atom or a C1-C4 alkyl, C1-C4 monohydroxyalkyl or C2-C4 polyhydroxyalkyl radical, R3 represents a hydrogen atom, a halogen atom, or a C1-C4 alkyl, C1-C4 monohydroxyalkyl or C1-C4 hydroxyalkoxy radical, and R4 represents a hydrogen atom or a C1-C4 alkyl radical, and (b) developing the color at acidic, neutral or alkaline pH using an oxidizing agent, wherein said oxidizing agent is added to said dye co

Abstract: The present invention provides a hair-cosmetic composition containing the following ingredients (A) and (B): (A): keratose which is cationized with a quaternary ammonium salt, and (B): a silicone derivative. The hair cosmetic composition imparts excellent gloss and smooth feel to damaged hair, while bonding and mending split ends of hair fibers.

Abstract: The present invention relates to a method making moxa extract formulations in a simple manner and an apparatus for operating moxibustion remedy in a convenient manner. The present invention provides a method of preparing the pharmaceutical moxa extract formulations comprising the steps of extracting a moxa-methanol extract; extracting a moxa-dichloromethane fraction; extracting a moxa-ethylacetate fraction; and making the moxa extract formulation, and an apparatus for electrical moxibustion which comprises a heating unit for generating heat at a certain temperature, a fixing unit for fixing and supporting the heating unit and indirectly transferring beat from the heating unit to the skin, an adiabatic unit for preventing heat from being scattered by forming a housing surrounding all upper and sides of the heating unit and the fixing unit, and a removable moxibustion pad attached and detached to the fixing unit.

Abstract: The present invention provides an antibacterial and antifungal resin composition comprising a polymeric resin and an antibacterial bis-pyridinium compound of the general formula wherein the two R1 may be the same or different, and each represent an alkyl group of 1 to 18 carbon atoms or an alkenyl group of 3 to 18 carbon atoms; the two R2 may be the same or different, and each represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, an alkyl group of 1 to 6 carbon atoms, or an alkoxy group of 1 to 3 carbon atoms; R3 represents an alkylene group of 2 to 18 carbon atoms, an alkenylene group of 3 to 18 carbon atoms, or a phenylene or xylylene group which may optionally be substituted by an alkyl group of 1 to 18 carbon atoms, an alkoxy group of 1 to 6 carbon atoms, or an alkoxycarbonyl group of 2 to 6 carbon atoms; Y1 represents —NHCO—, —CONH—, —NHCS—, —COO—, —COS—, —O— or —S—; Y2 represents

Abstract: Polymeric compounds of the formula: (D)n—M—(R1)m  (I) wherein (m) and (n) independently selected positive integers, preferably from about 1 to about 6 each; D is a residue of a biologically active moiety; M is a multifunctional linker/spacer moiety; and R1 is a polymer residue are disclosed. Methods of preparing the same and methods of treatment using the same are also included as part of the present invention.

Abstract: A method for ex vivo expansion of the number of hematopoietic cells using a culture medium comprising an extract prepared from a plant of the Tinospora species and a method of ex vivo expansion of the number of hematopoietic cells by inducing IL-6 production by using a culture medium comprising an extract from a plant of the Tinospora species are described.

Abstract: A method to follow the progression of metastasis of a primary tumor, which method comprises removing fresh organ tissues from a vertebrate subject which has been modified to contain tumor cells that express GFP and observing the excised tissues for the presence of fluorescence is disclosed. The fluorescence can also be monitored by observing the tissues in situ. Vertebrate subjects which contain GFP producing tumors are useful models to study the mechanism of metastasis, as well as to evaluate candidate protocols and drugs. In addition, subjects already harboring tumors can be treated so as to modify the endogenous tumors to contain GFP. This permits clinical applications. Finally, by injecting a contrast dye into a subject harboring a GFP-labeled tumor, angiogenesis in the tumor can be observed directly.

Abstract: Treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic agents is described. Ex vivo stimulation of cells, selection of specific V&bgr; subsets of stimulated cells and reinfusion of the V&bgr; subsets of stimulated cells is employed for cancer therapy.

Abstract: An enzymatic antimicrobial composition comprising a haloperoxidase, a hydrogen peroxide source, a halide source, and an ammonium source, in particular an ammonium salt or an aminoalcohol, in which there is a hitherto unknown synergistic effect between the halide and the ammonium source.

Abstract: Topoisomerase I polypeptides and DNA and RNA encoding such topoisomerase I polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such topoisomerase I for the treatment of infection, particularly bacterial infections. Antagonists against such topoisomerase I and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of topoisomerase I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding streptococcal topoisomerase I and for detecting the polypeptide in a host.

Abstract: Described herein are methods for producing recombinant forms of asparaginase derived from Wolinella succinogenes. In addition, methods for covalent modification of proteins, including asparaginases, by acylation are also provided. Certain embodiments provide for epitopic-labeling of the amino terminus of W. succinogenes asparaginase. Additional embodiments concern methods for the therapeutic utilization of the native, homotetrameric form of W. succinogenes asparaginase, as well as the use of epitopically-labeled or non-epitopically-labeled recombinant W. succinogenes asparaginase (or a covalently modified analog thereof) in the therapeutic treatment of malignant and non-malignant hematological disease and other diseases where asparagine depletion or deprivation would be efficacious or which respond to asparagine depletion or deprivation, as well as their potential utilization in the therapeutic treatment of autoimmune diseases such as rheumatoid arthritis, AIDS, and SLE.

Abstract: The invention provides a human nucleotide pyrophosphohydrolase-2 (NTPPH-2) and polynucleotides which identify and encode NTPPH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-2.

Abstract: Two chitinases from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus-inhibiting activity. One is an endochitinase and the other is a chitobiase. Both have molecular weights of 40 kDa and isoelectric points of 3.9. A &lgr;gtll recombinant encoding for the endochitinase has been prepared (ATCC 55338) and the gene encoding for the endochitinase has been removed from the DNA of the recombinant by the restriction enzyme, Not I. Endochitinases and chitobiases including the two purified from Trichoderma harzianum strain P1 demonstrate synergy with each other in anti-fungal effect.

Abstract: Compositions and methods are provided to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase. Preferrably the caseomorphinase is dipeptidyl peptidase IV and the gluteomorphinase is tyrosinase or phenylalaninase.

Abstract: Targeting molecules for use in delivering biological agents to non-polarized epithelial cells are disclosed. Upon delivery, the biological agent(s) are lethal to the epithelial cell. The targeting molecules may be used, for example, for the eradication of metastatic epithelial cells.

Abstract: The present invention is directed to antibodies and antibody fragments that bind specifically to the active conformation of human von Willebrand factor. Most preferred are recombinantly produced single chain variable immunoglobulin fragments. Because the antibodies or antibody fragments act only at the sites of thrombus formation and do not interfere with the normal activity of circulating platelets, they are particularly well suited for use as antithrombotic agents in a wide variety of applications.

Abstract: A method and a system is described for reducing non-target levels of specific molecules intended for diagnostic and/or therapeutic applications to vertebrate hosts, wherein said molecules are administered to a vertebrate host and kept therein for a certain time in order to be concentrate to the target by being attached thereto. The molecules which are not attached to the target are removed from the blood circulation system or at least reduced to a lower concentration by passing the blood through an extra-corporeal device.

Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.

Abstract: The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis.

Abstract: The present invention provides a purified preparation containing, for example, a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at least 5 amino acids in length and which effectively protect a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a polypeptide encoded by such a polynucleic acid; a vaccine comprising an effective amount of such a polynucleic acid or protein; antibodies which specifically bind to such a polynucleic acid or protein; methods of producing the same; and methods of protecting a pig against a PRRSV and treating a pig infected by a PRRSV.

Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

Abstract: The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLp's in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Polypeptide and lipopeptide vaccines, with and without adjuvants, also are disclosed.

Abstract: Compositions and methods for the prevention and treatment of neoplastic diseases and hypercholesterolemia are described. Individuals at a high risk of developing or having neoplasia or hypercholesterolemia undergoing conventional therapies may be treated with an effective dose of triterpene derivatives in citrus limonoids, polyphenolic flavonoid citrus compounds, tocotrienols or a combination of these agents.

Abstract: A combined vaccine for bacterial meningitis comprises Hib and MenC oligosaccharide conjugates.

Abstract: The use of hCG Beta-core or hCG fragments, deglycosylated hCG in the treatment of Kaposi's sarcoma is described. Inhibition of tumor production or regression on a variety of KS cell lines is shown. Purified hCG preparations do not inhibit the growth of KS cell lines.

Abstract: This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII M fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.

Abstract: The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and/or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and/or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and/or infectious agent which causes a porcine respiratory and reproductive disease.

Abstract: Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

Abstract: This application relates to the use of attenuated prokaryotic miccrooganism strains (such as Salmonella) expressing nucleic acid encoding HPV proteins as vaccines against HPV infection and he associated increased risk of cancer. In particular, the work shows that it is possible to assemble VLPs in a prokaryotic organism and that nasal immunization of mice with the strains HPV-specific conformationally dependent and neutralizing antibodies in serum and genital secretions. The experiments described herein show that it is also possible to assemble chimeric VLPs of a HPV including a fusion partner and that tumor protection can be induced.

Abstract: A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least one pharmaceutically acceptable and water-soluble salt of an organic anion and a metal cation.

Abstract: A fragrance sample is provided which is made from two plies of material. A wall is formed in the bottom ply which defines a well into which a fragrance sample is deposited. The top ply has a wall formed therein which interlocks with the bottom ply wall to cover and close the well. The two plies are then adhered together to form a liquid tight seal between the two plies.

Abstract: The present invention provides a decorative cosmetic composition that is visually distinct comprising a translucent or transparent particle and a cosmetic base. In addition, the present invention provides a decorative cosmetic composition that has both a functional effect, such as for cleansing or massage, and a distinct visual effect.

Abstract: A dental floss formed from a single hollow monofilament in the shape of a flattened tube. The monofilament is formed of a blend that includes a base polymer, a block copolymer and a compatibilizer.

Abstract: A composition for cosmetic products and a method for making the cosmetic products, the composition comprises particles of pigments and/or extender pigments, water-soluble metal salt, and one or more hydrophobidizing agents selected from hydrogenated lecithin, and water-soluble alkali salt of fatty acids, acylamino acids, and acyl collagen with the water-soluble metal salt and the one or more hydrophobidizing agents being prevented from chemically interacting with one another in the presence of ambient moisture prior to placement of the composition into an aqueous slurry by encapsulation or by entrapment of one of such materials.

Abstract: A composition, in particular a cosmetic composition, which can especially be in the form of an emulsion, a gel or a vesicle dispersion, the said composition comprising a pulverulent phase in an amount of less than or equal to 80% by weight relative to the total weight of the composition, this composition comprising at least one pigment and at least one antiperspirant. Use of such a composition in cosmetics, in particular for make-up, in order to improve the staying power of the color of the composition.

Abstract: A cosmetic or dermatological composition comprising, in an aqueous phase: i) a water-soluble or water-dispersible terephthalic copolyester oligomer comprising dicarboxylate repeat units of formula (I): [—CO—A—CO—O—(CH2—CH2O)n—]  (I) wherein A is 1,4-phenylene and sulfo-1,3-phenylene groups, n ranges from 1 to 4, at least 35 mol % of said units of formula (I) are units of formula (I), wherein A is a 1,4-phenylene group and n is equal to 1, at least 7 mol % of said units of formula (I) are units of formula (I), wherein A is a sulfo-1,3-phenylene group, and the weight-average molecular mass of said copolyester oligomer is less than 20,000, and ii) at least one silicone compound as an emulsion in the aqueous phase, and the composition is intended for making up keratinous substances.

Abstract: There is disclosed an aqueous formulation for pretanning leather, which formulation comprises (a) a reductive saccharide having a dextrose equivalent of 10 to 100, and (b) an aliphatic dialdehyde containing 2 to 8 carbon atoms, and which is devoid of mineral salts. The leather treated with the novel aqueous composition (wet white leather) is eminently suitable for further processing, especially for the manufacture of leathers which are devoid of heavy metals.

Abstract: A novel three component solvent system consisting of glyceryl triacetate, a substituted biphenyl, and a mixture of isoparafinic hydrocarbons is disclosed. The system is useful in the formulation of pesticides, and the use of the system to prepare emulsifiable concentrates and microemulsions is exemplified.

Abstract: A clear, one-phase, efficacious aqueous microemulsion of an agriculturally active pyrethroid insecticide for delivery at a high loading of active is provided herein which is free of nonylphenol ethoxylate.

Abstract: An inorganic antimicrobial composition has the formula AB2O4, wherein A and B are low temperature far infrared irradiating metals, A is Mg, Zn, Mn, Ni, Co, or Fe(II), B is Al, Cr(III), Mn(III) or Fe(III), and O is oxygen. An antimicrobial article is made by coating said composition on a porous honeycomb-shaped substrate. An organic antimicrobial article is made from a quarternary ammonium salt coated on a porous honeycomb-shaped substrate. Processes of making the antimicrobial articles are provided.

Abstract: A system and method for implanting pellets into myocardial tissue for treatment of coronary artery restenosis, ischemic heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.